ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 967,95
0,13%
Dow Jones
38 675,68
1,18%
DAX
18 039,93
0,26%
Brent Oil
83,475
0,42%
Bitcoin
64 457,46
0,72%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immuron Ltd (IMRN)

  7. Immuron Ltd (IMRN) Actualités

IMRN Immuron Ltd

2,52
0,00 (0,00%)
06 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Immuron Ltd IMRN NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 2,52 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,52
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
03/5/202412:00GLOBEImmuron Director Resignation
15/4/202412:00GLOBEImmuron to host Live Virtual Event
10/4/202412:00GLOBEImmuron Travelan® sales continued strong growth
07/3/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/3/202412:00GLOBEImmuron Announces Positive Results Support Travelan®..
28/2/202414:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202412:00GLOBEImmuron Presentation Australian Biologics Festival 2024
13/2/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/2/202412:00GLOBEImmuron achieves record Travelan® sales
08/2/202412:00GLOBEImmuron CEO, Steven Lydeamore Investor Webinar Presentation
16/1/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/1/202412:00GLOBEImmuron achieves record half yearly Travelan® sales
22/12/202313:21EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/12/202312:00GLOBEImmuron Clinical Trials Update
04/12/202312:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202312:00GLOBEImmuron Announces First Patients Enrolled in Campylobacter..
28/11/202312:33GLOBEImmuron CEO, Steven Lydeamore Investor Webinar Presentation
28/11/202312:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202313:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202300:00GLOBEImmuron CEO Steven Lydeamore Investor Webinar Presentation
13/11/202314:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202312:21GLOBEImmuron CEO Steven Lydeamore presented at AusBioInvest
23/10/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/10/202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/10/202312:00GLOBEImmuron Announces Travelan® Clinical Study Cohort 2..
11/10/202312:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202312:00GLOBEImmuron achieves record quarterly Travelan® sales
28/9/202314:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/9/202312:18EDGAR2Form 20-F - Annual and transition report of foreign private..
13/9/202312:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/9/202312:00GLOBEImmuron achieves record monthly Travelan® sales
11/9/202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202312:00GLOBEImmuron CEO, Steven Lydeamore to present at H.C. Wainwright
30/8/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202312:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202312:00GLOBEImmuron to present at the Military Health System Research..
09/8/202312:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/7/202312:00GLOBEImmuron Announces First Patients Enrolled in Travelan®..
25/7/202303:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202312:00GLOBEImmuron CEO, Steven Lydeamore to present at Bioshares
11/7/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202312:00GLOBEImmuron Business Update - Ateria Health launches Juvia™ in..
05/7/202312:00GLOBEImmuron FY23 Sales increase 136% on FY22 Sales
30/6/202312:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/6/202312:00GLOBEImmuron Chairman Transition
22/6/202312:00GLOBEImmuron Business Update: Letter to Shareholders

Dernières Valeurs Consultées

NASDAQ
IMRN
Immuron
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés